1.Childhood-onset Takayasu arteritis: Unique characteristics and outcomes from a Singapore cohort.
Amanda Xin Yi YAP ; Junjie HUANG ; Kai Liang TEH ; Lena DAS ; Yun Xin BOOK ; Sook Fun HOH ; Xiaocong GAO ; Thaschawee ARKACHAISRI
Annals of the Academy of Medicine, Singapore 2025;54(9):531-541
INTRODUCTION:
Takayasu arteritis is the most common large-vessel vasculitis in childhood, but there is a lack of literature regarding childhood-onset Takayasu arteritis (c-TAK) in Southeast Asia. We aim to describe a c-TAK cohort in Singapore and highlight a unique subset that first presents with Kawasaki-like disease (KD).
METHOD:
A single-centre cohort study in Singapore of consecutive children diagnosed with c-TAK between 2002 and 2023 was performed. Demographic and clinical features, laboratory and angiographic findings, treatment, and outcomes were summarised. Disease activity was evaluated using the Paediatric Vasculitis Disease Activity Score and inflammatory markers.
RESULTS:
Twenty-three patients, fulfilling both the EULAR/ PRINTO/PReS and ACR/EULAR 2022 criteria, were recruited. The most common clinical features at diagnosis were fever (15, 65%) and neurological symptoms (11, 48%, half of which presented with stroke), while the most prevalent angiographic pattern by Hata's classification was Type V (21, 91%). Eight children (35%) initially presented with refractory KD, and these patients were significantly younger, more male-predominant, and had higher inflammatory markers at diagnosis; all of them had coronary artery involvement, but none had intracranial vascular findings. Of the entire cohort, 16 (70%) achieved inactive disease on medications with a median duration of 6 months (interquartile range [IQR]: 4-11), and 8 (35%) achieved remission off medications with a median duration of 43 months (IQR 35-60).
CONCLUSION
Our c-TAK cohort has high proportions of neurological involvement and stroke. This is also the first cohort study to describe a distinct group of patients who first presented with refractory KD.
Humans
;
Takayasu Arteritis/complications*
;
Singapore/epidemiology*
;
Male
;
Female
;
Child
;
Adolescent
;
Age of Onset
;
Mucocutaneous Lymph Node Syndrome/diagnosis*
;
Cohort Studies
;
Child, Preschool
;
Fever/etiology*
;
Stroke/epidemiology*
;
Retrospective Studies
3.Multisystem inflammatory syndrome in children in Singapore.
Karen Donceras NADUA ; Chia Yin CHONG ; Kai Qian KAM ; Yee Hui MOK ; Jonathan Tze Liang CHOO ; Joyce Ching Mei LAM ; Jiahui LI ; Natalie Woon Hui TAN ; Chee Fu YUNG ; Su Wan Bianca CHAN ; Kai Liang TEH ; Lena DAS ; Thaschawee ARKACHAISRI ; Koh Cheng THOON
Annals of the Academy of Medicine, Singapore 2022;51(11):669-676
INTRODUCTION:
Multisystem inflammatory syndrome in children (MIS-C) is a rare inflammatory syndrome with multisystem involvement affecting children exposed to COVID-19. This condition is rarely reported in East Asia and was not detected in Singapore until 2021. We present 12 cases of MIS-C diagnosed in KK Women's and Children's Hospital (KKH) from October 2021 to December 2021.
METHOD:
We conducted an observational study on cases fulfilling the Singapore Ministry of Health criteria for MIS-C from January 2020 to December 2021 in KKH. Medical records were reviewed to obtain information on clinical presentation, disease course, treatment received and outcomes.
RESULTS:
In the 12 cases detected, the median age was 7.50 years (interquartile range 4.00-9.25); 8 were male. All patients had mucocutaneous symptoms similar to Kawasaki disease. Other commonly involved systems were: haematological (coagulopathy 100%, lymphopaenia 91.70% and thrombocytopaenia 75.00%), gastrointestinal (75.00%) and cardiovascular (83.30%). Six patients (50.00%) had shock and were admitted to the intensive care unit. The majority of patients received treatment within 2 days of hospitalisation with intravenous immunoglobulin (IVIg) and steroids. All survived; the majority had normal echocardiograms and no long-term organ sequelae at 6 months post-discharge.
CONCLUSION
MIS-C emerged in Singapore as the incidence of COVID-19 in the community increased in 2021. The clinical presentation of our patients is similar to earlier reports, with some significant differences from Kawasaki disease. Multidisciplinary management, timely diagnosis, and early initiation of treatment with IVIg and steroids likely contributed to comparatively good outcomes. Our cases highlight the need for continued awareness of MIS-C among physicians, and surveillance of its incidence, short- and long-term outcomes.
Child
;
Humans
;
Female
;
Male
;
COVID-19/epidemiology*
;
Mucocutaneous Lymph Node Syndrome
;
Immunoglobulins, Intravenous/therapeutic use*
;
Aftercare
;
Singapore/epidemiology*
;
Patient Discharge

Result Analysis
Print
Save
E-mail